ClinicalTrials.gg
Not yet recruitingNCT07554885Updated May 26, 2026

Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation

An interventional study of Spirulina-Bifidobacterium capsule and Fish oil-grape seed-blueberry soft capsule in Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions and Neoplasms, sponsored by Guangzhou Institute of Respiratory Disease. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by Guangzhou Institute of Respiratory Disease · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · China.

Planned enrollment
15th of 33
60 · median 44
Started
2026
with 1 other
No phase
8 of 53
2 open now
Primary completion
2028-12
later than 14 of 14 live
Registered
52nd of 53
by date

Among the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, this one is the 15th largest by planned enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, reaches primary completion later than 14 of the 14 other live ones, and was the 52nd registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

14 of the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-center, open-label, randomized controlled clinical trial evaluating whether the addition of a nutritional therapy regimen (Spirulina-Bifidobacterium capsules, fish oil-grape seed-blueberry soft capsules, and Ganoderma spore oil) to standard glucocorticoid therapy improves outcomes in patients with Grade 3-4 immune checkpoint inhibitor-related pneumonitis (CIP), compared with standard glucocorticoid therapy alone.

A total of 60 patients with malignancies who develop Grade 3-4 CIP (per CTCAE v5.0) after at least one cycle of immune checkpoint inhibitor therapy will be randomized 1:1 to the experimental or control arm. The primary endpoints are time to pneumonitis downgrading and the proportion of patients achieving downgrading at 3 months.

Read the detailed description

BACKGROUND:

Immune checkpoint inhibitor-related pneumonitis (CIP) accounts for the largest proportion of fatal immune-related adverse events. Approximately 30% of patients respond poorly to corticosteroid therapy, and long-term high-dose steroids increase the risk of secondary infection. Oxidative stress plays a key role in pulmonary fibrosis. The investigational nutritional products have demonstrated antioxidant and immunomodulatory properties in preclinical and clinical studies.

OBJECTIVES:

Primary: To evaluate the efficacy of nutritional therapy combined with glucocorticoids versus glucocorticoids alone in treating CIP, as measured by time to pneumonitis downgrading and the 3-month downgrading rate.

Secondary: To evaluate safety (AE/SAE incidence, severity), total steroid dose and duration, and changes in 6-minute walk distance (6MWD), modified Medical Research Council dyspnea scale (mMRC), St George's Respiratory Questionnaire (SGRQ), and Leicester Cough Questionnaire (LCQ).

Exploratory: To analyze the relationship between treatment response and changes in T-cell subsets, inflammatory cytokines (IL-1 beta, IL-6, IL-10), KL-6, ALC, CD4+ Th1/Th17, Tregs, NLR, AEC, and gut microbiome.

STUDY DESIGN:

Sixty eligible participants will be randomized 1:1 to:

  • Experimental arm: Spirulina-Bifidobacterium capsules 1080 mg twice daily orally, fish oil-grape seed-blueberry soft capsules 1200 mg twice daily orally, and Ganoderma spore oil 800 mg twice daily orally, plus methylprednisolone (dose and tapering per investigator assessment, referencing NCCN Guidelines 2025 v1).
  • Control arm: Matching placebo orally plus methylprednisolone (per NCCN Guidelines 2025 v1), tapered until symptoms and imaging improve and then discontinued.

Pneumonitis imaging (chest X-ray or CT) will be assessed at baseline and on Days 3, 7, 14, 28, 42, and 56, and at 2-3 months post-treatment, with additional imaging as clinically indicated. Pneumonitis grade will be determined by an Independent Radiologic Review Committee (IRRC) blinded to treatment allocation.

PARTICIPANTS:

Adults 18-75 years of age with histologically or cytologically confirmed malignancy, who have received at least one cycle of immune checkpoint inhibitor therapy, and who develop Grade 3-4 CIP per CTCAE v5.0 and radiologic grading.

FOLLOW-UP:

All participants will be followed for 2 years or until death, with contacts every 90 (plus or minus 7) days.

03

Conditions studied

  • Immune Checkpoint Inhibitor-Related Pneumonitis
  • Drug-Related Side Effects and Adverse Reactions
  • Neoplasms

Keywords

  • Immune checkpoint inhibitor
  • Pneumonitis
  • Immune-related adverse events
  • Glucocorticoids
  • Spirulina
  • Bifidobacterium
  • Grape seed proanthocyanidin
  • Ganoderma spore oil
  • Antioxidant
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation with full understanding of the study and signed form.
  2. Age 18 to 75 years (inclusive) on the day of informed consent signing.
  3. or cytologically confirmed .
  4. Received at least one cycle of therapy.
  5. Grade 3-4 immune-related pneumonitis (per v5.0 and radiologic grading).
  6. performance status 0-2, with expected survival of more than 3 months.
  7. Adequate organ function based on laboratory results (without transfusion, apheresis, erythropoietin, or granulocyte colony-stimulating factor support within 14 days before the first dose). Women of must have a negative serum pregnancy test within 7 days before first dose.

Exclusion criteria

Exclusion Criteria:

  1. Severe cardiac, cerebrovascular, renal, hematologic, or other serious systemic disease, including: Class III-IV heart failure; acute myocardial infarction or unstable angina within 6 months; severe post-stroke functional impairment (mRS greater than or equal to 3); progressive neurodegenerative disease; Class B or C liver disease or acute liver failure; CKD stage 4-5 ( less than 30 mL/min/1.73 m2) or requiring dialysis; less than 1.5 x 10\^9/L, count less than 50 x 10\^9/L, or Grade 3 or higher anemia ( less than 8 g/dL).
  2. Severe allergic constitution or to the study treatment.
  3. Significant psychiatric or psychological disorder, or doubts about the treatment plan.
  4. Investigator judgment that the patient is unsuitable for the trial (e.g., poor follow-up adherence, refusal of supportive care).
  5. Use of anti-tumor traditional Chinese medicine within 14 days before first dose.
  6. History of or active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
  7. Severe acute or chronic infection.
  8. Known alcohol or drug abuse history.
  9. Pregnancy or breastfeeding.
  10. Use of antibiotics, probiotic food, or microecological preparations within 2 weeks before enrollment.
  11. Prior treatment-related lung injury: (a) targeted-therapy-related pulmonary toxicity (prior EGFR-TKI, ALK inhibitor, VEGF inhibitor, or antibody-drug conjugate causing interstitial lung disease or pneumonitis that has not fully resolved, with radiologic fibrosis or persistent functional impairment); (b) thoracic radiation-related lung injury (radiation pneumonitis or radiation fibrosis with irreversible CT findings).
  12. Use of another drug within 28 days before first dose that, per investigator judgment, would interfere with evaluation of study treatment.
  13. Gastrointestinal disorder precluding oral administration.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Nutritional Therapy Plus Glucocorticoid

    Participants receive Spirulina-Bifidobacterium capsules 1080 mg orally twice daily, fish oil-grape seed-blueberry soft capsules 1200 mg orally twice daily, and Ganoderma spore oil 800 mg orally twice daily, in addition to methylprednisolone administered per investigator assessment (referencing NCCN Guidelines 2025 v1), until pneumonitis resolution, intolerance, or death.

    Dietary Supplement: Spirulina-Bifidobacterium capsule · Dietary Supplement: Fish oil-grape seed-blueberry soft capsule · Dietary Supplement: Ganoderma spore oil · Drug: Methylprednisolone

  • Placebo comparator
    Placebo Plus Glucocorticoid

    Participants receive matching placebo capsules (identical in appearance, color, shape, size, odor, taste, packaging, label, route, and dosing frequency to the investigational nutritional products) in addition to methylprednisolone administered per investigator assessment (referencing NCCN Guidelines 2025 v1), tapered until symptoms and imaging improve and then discontinued.

    Drug: Methylprednisolone · Other: Matching placebo

Interventions

  • Dietary supplementSpirulina-Bifidobacterium capsule

    1080 mg orally twice daily, from randomization until pneumonitis resolution, intolerance, or death.

  • Dietary supplementFish oil-grape seed-blueberry soft capsule

    1200 mg orally twice daily, from randomization until pneumonitis resolution, intolerance, or death.

  • Dietary supplementGanoderma spore oil

    800 mg orally twice daily, from randomization until pneumonitis resolution, intolerance, or death.

  • Dose and tapering schedule per investigator assessment, referencing NCCN Guidelines 2025 version 1 for immune-related pneumonitis, continued until clinical and radiologic improvement and then tapered to discontinuation.

  • OtherMatching placebo

    Oral placebo capsules identical in appearance, color, shape, size, odor, taste, packaging, label, route, and dosing frequency to the investigational nutritional products, administered to maintain blinding and control for non-specific effects.

06

What researchers measure

Primary outcomes

  1. Time to immune-related pneumonitis downgrading

    Time from randomization to the first imaging assessment, confirmed by the Independent Radiologic Review Committee, showing a reduction of at least 1 grade in pneumonitis severity compared with baseline, per CTCAE v5.0 and radiologic grading.

    Time frame: From randomization until first IRRC-confirmed pneumonitis grade reduction of at least 1 grade, assessed up to 6 months

  2. Proportion of participants with pneumonitis downgrading at 3 months

    Proportion of participants in each arm with an IRRC-confirmed reduction of at least 1 pneumonitis grade from baseline within 3 months after randomization.

    Time frame: 3 months (plus or minus 7 days) after randomization

Secondary outcomes

  1. Change from baseline in 6-minute walk distance (6MWD)

    Distance (meters) walked in 6 minutes on a flat, hard surface, measured according to a standardized protocol by trained personnel.

    Time frame: Baseline, Day 28, Day 56, Month 2-3

  2. Change from baseline in modified Medical Research Council (mMRC) dyspnea scale

    Self-reported dyspnea severity on the 0-4 mMRC scale, where 0 indicates no dyspnea except with strenuous exercise and 4 indicates dyspnea too severe to leave the house.

    Time frame: Baseline, Day 28, Day 56, Month 2-3

  3. Change from baseline in St George's Respiratory Questionnaire (SGRQ) total score

    Validated Chinese version of SGRQ; total score ranges 0-100, higher scores indicate worse respiratory-related quality of life.

    Time frame: Baseline, Day 28, Day 56, Month 2-3

  4. Change from baseline in Leicester Cough Questionnaire (LCQ) score

    Validated Chinese version of LCQ; total score ranges 3-21, higher scores indicate better cough-related quality of life.

    Time frame: Baseline, Day 28, Day 56, Month 2-3

  5. Total cumulative corticosteroid dose

    Total cumulative glucocorticoid dose used for CIP, expressed in methylprednisolone-equivalent milligrams.

    Time frame: From randomization to end of corticosteroid treatment, up to approximately 6 months

  6. Duration of corticosteroid treatment

    Total number of days on glucocorticoid therapy for CIP, from initiation to final discontinuation.

    Time frame: From randomization to end of corticosteroid treatment, up to approximately 6 months

  7. Incidence of adverse events, treatment-related adverse events, and serious adverse events

    Incidence, severity (CTCAE v5.0), and relationship to study treatment of all AEs, TRAEs, and SAEs.

    Time frame: From randomization through 30 days after last dose; SAEs collected through 90 days after last dose

Other outcomes

  1. Change in serum KL-6 (Krebs von den Lungen-6)

    Time frame: Baseline, Day 28, Day 56, Month 2-3

  2. Change in serum inflammatory cytokines (IL-1 beta, IL-6, IL-10)

    Time frame: Baseline, Day 28, Day 56, Month 2-3

  3. Change in immune cell subsets (ALC, CD4+ Th1/Th17, Tregs, NLR, AEC)

    Time frame: Baseline, Day 28, Day 56, Month 2-3

07

Study locations

1 site
  • The First Affiliated Hospital of Guangzhou Medical University, Department of Pulmonary Oncology
    Guangzhou, Guangdong 510120, China
    • Fei Wang · Contactdoctorlzk@163.com · +86 18355293991
    • Chengzhi Zhou, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — The decision regarding sharing of individual participant data has not yet been made. A plan will be provided before publication of study results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2028, 32 months later.

Of 71 non-industry interventional studies with no phase under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 32 months is above that.

Counting every sponsor, half of 73 studies reached it within 26 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
Apr 28, 2026
StartEst.
Apr 2026
Primary completionEst.
Dec 2028
CompletionEst.
Oct 2029
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07554885
Lead sponsor
Guangzhou Institute of Respiratory Disease
Responsible party
Zhou Chengzhi (Principal Investigator, Guangzhou Institute of Respiratory Disease) — Principal investigator
First posted
Apr 28, 2026
Start date
Apr 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Oct 2029 (estimated)
Last update
May 26, 2026

Study contacts

Fei Wang
Contact
doctorlzk@163.com
+86 18355293991
Chengzhi Zhou, MD
principal investigator · The First Affiliated Hospital of Guangzhou Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion